Bedrijfsoverzicht
Daré Bioscience, Inc. is a biotechnology enterprise focused on developing and commercializing therapies across specific therapeutic areas, including contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health within the United States. The company operates within the broader healthcare sector, specifically the biotechnology industry, which is characterized by high research and development expenditures and a focus on innovative drug therapies and medical devices. As of the latest data, the company maintains a market capitalization of $26.64M and employs a workforce of 21 individuals to support its operational and development activities. The annual revenue generated over the trailing twelve months stands at $1.03M, a figure that, when juxtaposed against the market cap, indicates a small-cap status typical of early-stage or development-focused biotech firms where valuation is often disconnected from current sales figures due to the potential future value of the pipeline. This disparity between the $26.64M market cap and the modest $1.03M in revenue highlights the market's pricing in significant future growth potential or the inherent risks associated with a company that has yet to achieve commercial profitability.
Financiële gezondheid
The financial statements reveal a company with significant revenue generation challenges relative to its profitability, reporting a trailing twelve-month revenue of $1.03M against a net income of $-13,399,274. The substantial gap between the modest revenue figure and the massive net loss of approximately $13.4 million underscores a cost structure dominated by high operating expenses, likely driven by research, development, and general administrative costs common in the biotechnology sector. Furthermore, the company reports an EBITDA of $-11,917,848 and a free cash flow of $-4,802,669, indicating that the business is burning through cash reserves to fund its operations and development efforts. The liquidity position is assessed through a cash balance of $24.71M, which provides a buffer against the $2.66M in total debt, though the debt-to-equity ratio of 93.44 suggests a highly leveraged capital structure relative to shareholder equity. Despite the high leverage, the current ratio of 1.14 indicates that the company possesses slightly more current assets than current liabilities, suggesting a marginally comfortable short-term liquidity position. The profitability metrics are stark, with a gross margin of 71.3%, an operating margin of -143.7%, and a profit margin of 0.0%, reflecting that operating expenses exceed total revenue significantly. Return on equity is listed as N/A due to the lack of positive retained earnings, while the return on assets stands at -31.0%, revealing that the company's asset base is currently generating negative returns.
Waarderingsbeoordeling
Valuation metrics for Daré Bioscience, Inc. present a complex picture due to the absence of traditional profitability measures, with a trailing twelve-month P/E ratio listed as N/A. However, the forward P/E is calculated at 3.13, a figure that implies the market anticipates a significant turnaround or substantial earnings growth in the near future to justify even a low multiple. The price-to-book ratio sits at 9.34, indicating that the stock is trading at a substantial premium relative to its net asset value, a common phenomenon for biotech companies with valuable intellectual property or pipeline assets. Alternative valuation metrics include a price-to-sales ratio of 25.86 and an EV/EBITDA of -0.39, which suggests the market is pricing the company based on its sales potential and pipeline rather than current earnings power. The stock's price volatility is captured by a beta of 0.90, meaning the share price tends to move in line with the broader market, neither exhibiting extreme defensive characteristics nor high speculative volatility. The trading range over the last year has been between a 52-week low of $1.27 and a 52-week high of $9.19, providing a historical context for the current valuation levels relative to the company's recent price history.
Growth & Income
Growth metrics for the company are currently unavailable, with revenue growth year-over-year and earnings growth year-over-year both listed as N/A. This lack of historical growth data is typical for a company in the early commercialization or development phase where consistent year-over-year comparisons may not yet be established or reported. Regarding income, the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status is consistent with the financial profile of a biotechnology firm that must reinvest all available capital, including its $24.71M cash reserves, into research and development to advance its therapies in areas such as contraception and infectious disease. Consequently, the overall growth and income profile is defined entirely by the potential for future commercial success rather than current cash distributions or established revenue expansion rates. The company's strategy relies on the successful execution of its product pipeline rather than providing immediate income returns to shareholders.